News

Given the scope of the risk, attention has turned to metabolic hormones that regulate appetite, satiety, and glucose metabolism, particularly glucagon-like peptide-1 (GLP-1). Its appetite ...
About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...
Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.
GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...
Ecnoglutide is a GLP-1 receptor agonist, part of a growing class of drugs that help control blood sugar and reduce hunger.
In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these ...
Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...